Group 1 - The top three companies with the highest short position ratios are China COSCO Shipping (01919) at 17.74%, Vanke (02202) at 17.56%, and Dongfang Electric (01072) at 17.36% [1][2] - The companies with the largest absolute increase in short position ratios are Neway Group (01686) with an increase of 2.33%, China Ship Leasing (03877) with an increase of 2.23%, and Pacific Shipping (02343) with an increase of 1.78% [1][2] - The companies with the largest absolute decrease in short position ratios are Zhaoyan New Drug (06127) with a decrease of -1.92%, Lens Technology (06613) with a decrease of -1.51%, and Country Garden (02007) with a decrease of -1.48% [1][3] Group 2 - The latest short position ratios for the top ten companies show China COSCO Shipping (01919) at 17.74%, Vanke (02202) at 17.56%, and Dongfang Electric (01072) at 17.36% [2] - The companies with the largest increases in short position ratios include Neway Group (01686) from 3.65% to 5.99%, China Ship Leasing (03877) from 0.74% to 2.97%, and Pacific Shipping (02343) from 5.02% to 6.80% [2] - The companies with the largest decreases in short position ratios include Zhaoyan New Drug (06127) from 7.94% to 6.02%, Lens Technology (06613) from 8.32% to 6.80%, and Country Garden (02007) from 3.02% to 1.54% [3][4]

Core Viewpoint - The actual controller of Zhaoyan New Drug, Zhou Zhiwen, has terminated his plan to reduce shareholdings in the company, having sold a total of 14,979,000 shares within a specified period, resulting in significant cash proceeds. Group 1: Shareholding and Reduction Plan - Zhou Zhiwen held 74,725,981 shares before the reduction plan, representing 9.9704% of the total share capital [1] - The reduction plan was first disclosed on December 30, 2025, allowing for a maximum reduction of 14,980,000 shares, which is 20.0466% of his holdings and 1.99873% of the total share capital [1] - The actual reduction occurred from January 22 to January 28, 2026, with a total of 14,979,000 shares sold [2] Group 2: Financial Details of the Reduction - The shares were sold at a price range of 34.78 to 42.19 yuan per share, resulting in total proceeds of 567,606,657.9 yuan [1][2] - The reduction was completed with only 1,000 shares remaining unsold, achieving a reduction ratio of 1.99894% [2] - Following the reduction, Zhou Zhiwen's remaining shareholding is 59,746,981 shares, which is 7.9732% of the total share capital [2] Group 3: Historical Context - Since November 5, 2020, Zhou Zhiwen has cumulatively reduced his holdings by 14,113,200 shares, realizing approximately 915 million yuan in cash [2] - The actual controllers of Zhaoyan New Drug are identified as Feng Yuxia and Zhou Zhiwen, a couple [3]

Core Viewpoint - The medical sector is showing signs of recovery in 2026, driven by policy clarity and the realization of innovative outcomes, leading to increased investment interest in medical ETFs [1][19]. Group 1: Current Core Logic and Positive Factors in the Medical Sector - The transition from "selling expectations" to "performance realization" is evident, with domestic medical device innovations gaining global recognition, thus becoming a new growth engine for the industry [3][21]. - The medical sector is experiencing a high proportion of companies meeting or exceeding their 2025 performance forecasts, indicating a favorable industry outlook [3][21]. - The recent surge in AI medical technologies is not just speculative but demonstrates clear cost-reduction and efficiency-enhancing capabilities in hospital operations and drug development [4][23]. Group 2: Policy Environment Changes - The policy environment has shifted from a "speed over quality" approach to one of "value co-creation," with recent signals indicating a more favorable stance on centralized procurement and medical insurance negotiations [6][24]. - Optimizations in the approval process for innovative medical devices and continuous improvements in procurement rules are expected to enhance the competitive landscape and restore profitability for companies [8][26]. - The introduction of a market exclusivity period in the revised Drug Administration Law is expected to boost long-term investment confidence in pharmaceutical R&D [9][27]. Group 3: Financial Support for Medical Equipment Updates - The national "two new" policy, focusing on large-scale equipment updates and consumer goods replacement, has allocated 62.5 billion yuan in special bonds to support medical equipment upgrades, benefiting listed companies in the medical device sector [10][28]. - There is a significant demand for replacing outdated medical equipment in domestic healthcare institutions, coupled with policies favoring domestic alternatives, leading to increased orders and market share for leading companies in imaging, surgical robots, and in-vitro diagnostics [10][28]. Group 4: Reasons for Recent Fund Inflows into Medical ETF (512170) - The medical ETF (512170) has seen substantial inflows, with a single-day capital increase of 499 million yuan on January 28, 2026, and a total of 1.8 billion yuan over nine consecutive trading days, reflecting a shift in market sentiment towards value recovery [1][19][14]. - The medical ETF is currently one of the largest medical-themed ETFs in A-shares, with a market size exceeding 26 billion yuan, driven by high cost-effectiveness and a consensus on bottom valuations [14][32]. - The ETF closely tracks the CSI Medical Index, with significant allocations in medical devices (53.17%) and medical services, making it an attractive option for both institutional and retail investors [14][32][34].

Market Overview - The market has shifted back to high dividend and low valuation stocks, with a notable rebound in the "drinking and medicine" sector, particularly in pharmaceuticals and healthcare [1][12] - Major healthcare stocks such as United Imaging, WuXi AppTec, and Mindray Medical have all risen over 2%, while the largest healthcare ETF (512170) ended a three-day decline with a 1.4% increase, trading at 9.65 billion yuan [1][12] Fund Inflows - The healthcare sector has attracted significant "bottom-fishing" capital, with the healthcare ETF (512170) seeing a single-day inflow of 4.99 billion yuan, marking a total of 18 billion yuan in net inflows over nine consecutive trading days [1][14] - The ETF's current PE valuation is still below 60% of the historical range over the past decade, indicating a favorable cost-performance ratio for investors [3][14] Earnings Forecasts - Among the 14 disclosed stocks for 2025 earnings forecasts, 10 are expected to achieve double-digit growth, with Lepu Medical projecting a net profit increase of 386% [3][14] - Key players in the CXO sector, including Zhaoyan New Drug and Boteng Co., are also expected to see their profits double [3][14] AI and Healthcare - The AI healthcare sector is gaining attention, with Huawei Cloud set to launch a smart healthcare platform on February 1, which will integrate top medical resources and cutting-edge technology [3][14] Pharmaceutical Sector Performance - The pharmaceutical sector is showing significant value, with the newly released "Drug Administration Law Implementation Rules" promoting drug research and development, including fast-track approval processes for new drugs [7][18] - The pharmaceutical ETF (562050) has seen a net inflow of over 12 million yuan in the past five days, ending an 11-day decline with a slight increase of 0.59% [5][16] Company-Specific Earnings - The pharmaceutical ETF has disclosed earnings forecasts for 9 stocks, with 8 expected to see profit increases, including Tonghua Dongbao, which anticipates a 30-fold increase in net profit [7][18] - Other companies like Sanofi and Yiling Pharmaceutical are also projected to achieve significant profit growth [7][18] Investment Tools - Investors are encouraged to focus on the pharmaceutical ETF (562050) and its associated funds, which track the top 50 pharmaceutical companies in A-shares, balancing innovation and traditional medicine [7][18]

Core Viewpoint - The actual controller of Zhaoyan New Drug (06127), Zhou Zhiwen, announced a share reduction plan, intending to reduce his holdings by up to 14.98 million shares, which represents 20.0466% of his total shares and 1.99873% of the company's total share capital [1] Summary by Sections - **Share Reduction Plan**: Zhou Zhiwen disclosed a plan to reduce his holdings by a maximum of 14.98 million shares through centralized bidding or block trading on the Shanghai Stock Exchange within three months after the announcement [1] - **Execution of the Plan**: As of January 29, 2026, Zhou Zhiwen had reduced his holdings by 14.979 million shares using block trading and centralized bidding methods, and he decided to terminate the reduction plan ahead of schedule [1]

Core Viewpoint - The company, Zhaoyan New Drug (603127), announced a share reduction plan by its actual controller, Zhou Zhiwen, which involves selling up to 14.98 million shares, representing 20.0466% of his holdings and 1.99873% of the company's total share capital [1] Summary by Relevant Sections - **Share Reduction Plan**: Zhou Zhiwen disclosed a plan to reduce his holdings starting from December 30, 2025, allowing for a period of three months post-announcement to sell shares through the Shanghai Stock Exchange [1] - **Execution of the Plan**: As of January 29, 2026, Zhou Zhiwen successfully reduced his holdings by 14.979 million shares through block trades and competitive bidding, and subsequently decided to terminate the reduction plan ahead of schedule [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 关于股东提前终止减持 A 股股份计划暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 馮宇霞 董事長 中 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2026-005 北京昭衍新药研究中心股份有限公司 关于股东提前终止减持 A 股股份计划暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 2025 年 12 月 30 日披露减持计划公告前，北京昭衍新药研究中心股份有限公 司（以下简称"公司"）实际控制人之一周志文持有公司股票 74,725,981 股，占公 司总股本 9.9704%，其持有的股份来源于首发前限售股份及公司资本公积金转增 股份等。 减持计划的实施结果情况 周志文于 2025 年 12 月 30 日披露了减持计划，自减持计划公告之日起 15 个 交易日后的 3 个月内通过上海证券交易所以集中竞价或大宗交易的方式减持不 超过 14,980,000 股,不超过其持有股份的 20.0466%，不超过公司当时总股本的 1.99873%。截至 2026 年 1 月 29 日，周志文以大宗交易及集中竞价交易的方式减 持公司 A 股股份 14,979,000 股，并 ...

Core Viewpoint - The company announced that one of its actual controllers, Zhou Zhiwen, reduced his holdings in the company's A-shares by a total of 14,979,000 shares, which represents approximately 1.99894% of the company's current total share capital. The reduction plan has been terminated ahead of schedule [1]. Summary by Relevant Sections - **Share Reduction Details** - Zhou Zhiwen executed the share reduction from January 22 to January 28, 2026, through centralized bidding and block trading methods [1]. - The total number of shares reduced was 14,979,000 [1]. - **Impact on Company Capital** - The reduction accounts for nearly 2% of the company's total share capital, indicating a significant change in ownership structure [1].

"AI不是替代人，而是让人从重复劳动中解放出来，成为'指挥官'。"日前在2026医药钉峰会上，钉钉大 健康行业负责人韦亚伟表示，AI正从信息、知识、数据、流程与协同五大层面，系统重构药企的工作 方式。 另据钉钉商业总裁杨猛在现场透露，目前已有超六成医药企业和超半数公立医院使用钉钉，打造全新 AI操作系统。 据了解，AI已在不同赛道医药企业的数智化浪潮中按下加速键。云南白药、信达生物、乐普生物、昭 衍新药、仙乐健康等一批代表企业已率先落地AI。 "百年老店"云南白药与钉钉共同打造了全集团的数字底座"白药钉"，数字化布局已贯穿中药材溯源、智 能工厂生产到AI辅助研发的各个环节。云南白药集团数字战略科学家李少春提出，未来的AI智能体须 具备"手和脚"，即与自动化流程和物理设备深度融合，方能释放真正的生产力。 （文章来源：中国经营报） A1录音卡能够实时捕捉并智能分析医药代表拜访场景，自动提取关键信息，生成结构化报告，使一线 市场情报得以无损耗、秒级同步至决策层，真正实现"让听见炮火的人指挥战斗"。 在数据处理与应用层面，AI带来了显著的民主化趋势。借助AI表格，业务人员无须依赖IT部门，便能 以自然语言对话的方式， ...